Return to content in this issue

 

Mepolizumab for the Treatment of Eosinophilic Cystitis: Reply

Trefond L1,2, Kahn JE3

1Service de Médecine Interne, CHU Gabriel Montpied, Clermont-Ferrand, France
2Université Clermont Auvergne, Inserm U1071, M2iSH, USCINRA 1382, Clermont-Ferrand, France
3National Reference Center for Hypereosinophilic Syndromes, CEREO, France; Université Paris-Saclay, Assistance Publique - Hôpitaux de Paris, Department of Internal Medicine, Ambroise Paré Hospital, Boulogne-Billancourt, France

J Investig Allergol Clin Immunol 2024; Vol 34(4) : 278-279
doi: 10.18176/jiaci.0980

Key words: Hypereosinophilic syndrome, Eosinophilic cystitis, Mepolizumab